SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK")...
Hence then, the article about huadong medicine co ltd and synerk reached a strategic cooperation to jointly develop a novel sirna drug snk 2726 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726 )
Also on site :
- Slate Auto says each $24,950 electric pickup truck will be profitable as it aims to be cash-flow positive next year
- Trump claims consumers are being ‘gouged’ by gas companies and orders DOJ price probe, as Bessent warns U.S. must avoid ‘foreign chokepoints’
- Crocs’ Platform Sandals With 'Squishy Cloud Comfort' and 'Excellent Arch Support' Are 60% Off for Amazon Prime Day